Welcome to your Saturday Biotech & Pharma Stock Market Recap

What’s to be covered in this hallowed scroll:

1. Overview of the biotech & pharma stocks that had the best & worst weeks (as measured by % change in price)

2. We’ll give you a calendar of whose announcing earnings in the upcoming week - and if they’re before the markets open (BMO) or after markets close (AMC).

3. One more thing we’ll have in future weeks - a recap of the more notable earnings calls the week previous.

Lastly - all three of the above will have sub-sections divided by:

1. Biotechnology (life sciences and the like)

2. Drug Manufacturers - General (this one includes big pharma)

3. Drug Manufacturers - Specialty and Pharma (everyone else that makes drugs, and then some)

And last thing - everything is in USD unless otherwise stated!

This weekend edition is a new feature at TLDR Biotech, so I’d love to get your feedback.

(You can also reach out to me on LinkedIn)

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

Biotechnology

For the winners - Virax Biolabs Group is up for no good reason, while Structure Therapeutics and Replimune had great reasons.

For the losers - a full clinical hold plummeted Biomea Fusion’s ticker, while for CNS Pharmaceuticals it’s nothing clinical, just the announcement of a 1-50 reverse stock split.

Upcoming Biotechnology Earnings Calls

Let’s hope Affimed keeps up the good vibes from earlier this week into next’s week earnings call.

Drug Manufacturers - General

Abbvie ticked higher on good clinical data from an ImmunoGen asset (which they got via their $10.1B buy-out of said biotech).

Another A-named pharma didn’t have an A-week - Amarin took a dive, not because their CEO changed again, but because their prize-commercial product won’t be covered by an undisclosed large national pharmacy benefit manager.

Upcoming Drug Manufacturers - General Earnings Calls

No earnings calls next week for this group. Instead, why not read up on a whole bunch of blockbusters with patents expiries coming up in the next 5 years?

Drug Manufacturers - Specialty & Generic

Esperion Therapeutic’s might be up this week due to future earning potential, while Evoke Pharma’s price is small enough for a light breeze to send up the stock price (though the shorts are circling).

The same breeze-stock-shifting potential can be said for the top three losers here, with prices under $0.50.

And sorry for you tree lovers out there, but mary-jane continues to be a bad investment - but that doesn’t stop some.

Upcoming Drug Manufacturers - Specialty & Generic Earnings Calls

Nothing for this group next week. Instead, why not read up on the OG NTF craze - the tulip?

That’s all for now - go enjoy your weekend!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️

Want to sponsor this newsletter and reach an audience of 100+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here